GC
REGN icon

Gibson Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Gibson Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-178
Closed -$187K – 79
2024
Q3 		$187K Sell
178
-92
-34% -$102K 0.04% 73
2024
Q2 		$284K Buy
+270
New +$262K 0.06% 54

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Gibson Capital's REGN Position: Q4 2024 in Review

Gibson Capital sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 178 shares — an estimated $187K sold.

Gibson Capital first reported a position in REGN in Q2 2024 and held it in 2 quarters. The position peaked at $284K in Q2 2024. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Gibson Capital reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Gibson Capital sold 178 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $187K.
  • Gibson Capital first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Gibson Capital's Regeneron Pharmaceuticals position peaked at $284K in Q2 2024.
  • 1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Gibson Capital's 13F filing for Q4 2024, filed 12 Feb 2025.